LT3001 + apixaban

**LT3001 + apixaban** is a combination of two agents under research for acute ischemic stroke. LT3001 (odatroltide) is a novel small synthetic peptide administered via intravenous infusion, developed for recanalizing occluded blood vessels and reducing reperfusion injury in acute ischemic stroke. Apixaban is a selective, oral, direct Factor Xa inhibitor that prevents thrombosis and embolic events by interrupting the blood coagulation cascade. Combining LT3001 with apixaban aims to synergistically improve outcomes by boosting blood clot resolution and preventing new clot formation, while monitoring for increased bleeding risk. The combination is being evaluated in clinical studies targeting patients with acute ischemic stroke[1][6][5].

Other names

LT3001 drug productLT-3001 drug productLT 3001 drug productLT3001 injectionLT-3001 injectionLT 3001 injectionapixabánapixabanum